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VCPAmyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterised by the degeneration
of upper and lower motor neurons. Recent advances in our understanding of some of the genetic causes of ALS,
such as mutations in SOD1, TARDBP, FUS and VCP have led to the generation of rodent models of the disease, as
a strategy to help our understanding of the pathophysiology of ALS and to assist in the development of therapeu-
tic strategies. This review provides detailed descriptions of TDP-43, FUS and VCPmodels of ALS, and summarises
potential therapeutics which have been recently trialled in rodent models of the disease. This article is part of a
Special Issue entitled: Animal Models of Disease.
© 2013 Elsevier B.V. All rights reserved.1. Introduction to ALS
Amyotrophic lateral sclerosis (ALS)wasﬁrst described over 140 years
ago by the French neurologist Charcot, whose observation ofmuscle atro-
phy and scarringwithin postmortem spinal cord led to its naming. ALS is a
progressive neurodegenerative disorder characterised by the degenera-
tion of upper and lower motor neurons. Loss of these neurons leads to a
deterioration of neuromuscular function, causing weakness, atrophy
and paralysis of skeletal muscles. The progression of ALS is usually rapid
and death typically occurs within 3–5 years of diagnosis.
Although the vast majority of ALS cases are sporadic (SALS),
approximately 10% are familial (FALS). The ﬁrst gene shown to beAmyotrophic lateral sclerosis;
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[1] and since this discovery, over 150 pathogenic mutations in SOD1
have been identiﬁed in ALS patients [2]. Recently, mutations in other
genes have also been found to be causative for FALS (Table 1). The
observation of Tar DNA binding protein 43 (TDP-43), a DNA and RNA
binding protein, as a large component of protein aggregates in post
mortem tissue from SALS and FALS cases [3] and the subsequent identi-
ﬁcation of pathogenic mutations in the TARDBP gene which encodes
TDP-43 [4,5] has strengthened the possibility that aberrant RNA
processing may play a signiﬁcant role in ALS pathogenesis. This had
been originally proposed following the identiﬁcation of ALS-causing
mutations in the SETX gene, which encodes a protein with roles in
DNA and RNA processing [6]. This association was signiﬁcantly
strengthened by the identiﬁcation of mutations in the DNA and RNA
binding protein fused in sarcoma/translocated in liposarcoma (FUS/
TLS, hereby referred to as FUS) as a cause of FALS [7,8]. The identiﬁcation
of the genetic causes of ALS is critical for advancing our understanding
of the pathophysiology of ALS, since these mutations form the basis of
the development of experimental models of the disease, the most valu-
able of which are animal models. This review will provide a detailed
overview of recent advances ofmodellingALS in rodents andwill brieﬂy
discuss potential therapeutics which have been recently trialled in ro-
dent models of ALS.
2. SOD1 rodent models of ALS
Missense mutations in the SOD1 gene on chromosome 21were the
ﬁrst identiﬁed causes of autosomal dominant FALS in 1993 [1].
Table 1
Currently known genetic causes of FALS. Table includes data onmutations identiﬁed to date, and the percentages known for which themutations account for FALS or SALS. – denotes that
this information is unclear.
Source: http://alsod.iop.kcl.ac.uk.
Protein/gene Chromosome Protein size (aa) Mutations FALS cases (%) SALS cases (%) Reference
SOD1/SOD1 21q22.11 154 166 ~20 1–3 Rosen et al. [1]
Alsin/ALS2 2q33.2 1657 19 – – Yang et al. [9]
Senataxin/SETX 9q34.13 867–1030 7 – – Chen et al. [6]
TDP-43/TARDBP 1p36.22 414 39 ~4 ~0.2–0.4 Kabashi et al. [4]; Sreedharan et al. [5]
FUS/FUS 16p11.2 526 27 ~4 ~0.2–0.4 Kwiatkowski et al. [7]; Vance et al. [8]
Optineurin/OPTN 10p13 571 3 – – Maruyama et al. [10]
VCP/VCP 9p13 475–644 4 – – Johnson et al. [11]
Angiogenin/ANG 14q11.1 147 18 – – Greenway et al. [12]
VAPB/VAPB 20q13.33 243 2 b1 – Nishimura et al. [13]
Ubiquilin-2/UBQLN2 Xp11.21 624 5 – – Deng et al. [14]
C9orf72/C9ORF72 9p21.2 481 GGGGCC repeat expansion ~20–40 ~10 DeJesus-Hernandez et al. [15]; Renton et al. [16]
Proﬁlin 1/PFN1 17p13.3 140 4 – – Wu et al. [17]
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into the aberrant functions of mutant SOD1 has formed the basis of
much of our understanding of the pathogenesis of ALS, in large part
through the generation and study of transgenic rodent models
overexpressing the mutant human SOD1 protein. However, despite
nearly 20 years of intensive research, an understanding of exactly
how mutant SOD1 causes motor neuron degeneration remains elusive.
SOD1 is a ubiquitous cytoplasmic and mitochondrial enzyme which
functions in a dimeric state to catalyse the breakdown of harmful reac-
tive oxygen species (ROS), thereby preventing oxidative stress. Due to
the damaging effects of ROS and their association with neurodegenera-
tive diseases, it was originally proposed that pathogenic mutations in
SOD1 may cause ALS as a result of a loss of dismutase activity [1].
Subsequent investigation failed to correlate mutant SOD1 activity with
pathogenicity [18] and in Sod1 knock-out mice (Sod1−/−), deﬁciency
of SOD1 did not result in motor dysfunction, at least up to 6 months
of age [19]. However, more recent characterisation of Sod1−/− mice
has revealed that although they do not have any motor neuron loss,
they have a signiﬁcant distal motor axonopathy, demonstrating the
important role of SOD1 in normal neuronal function [20–23]. Thus,
the signiﬁcant loss of motor neurons in transgenic mice expressing
mutant SOD1 is likely to result froma toxic gain-of-function. Investigation
of this gain-of-function has in large part been undertaken by studying
transgenic mouse models.
Shortly after the discovery of SOD1mutations in FALS [1], a transgenic
mouse model (SOD1G93A) of SOD1–ALS was developed, expressing
approximately 20–24 copies of the human coding sequence with the
G93A mutation, under control of the human SOD1 promoter [24]. Since
the development of this model, over twenty other SOD1 models have
been created and SOD1 transgenic rodents have been used as the
primary rodent models of ALS.
Mutant SOD1 transgenic rodents recapitulate many features of
ALS, including axonal and mitochondrial dysfunction, progressive
neuromuscular dysfunction, gliosis and motor neuron loss [24–29].
The majority of SOD1 transgenic rodents use the SOD1 promoter to
mimic normal expression of SOD1. However models utilising neuronal-
speciﬁc [30,31] or astrocytic promoters [32] have also been developed.
Such transgenic mice have been important in understanding the
non-cell autonomous nature of ALS. Overexpression of mutant SOD1 is
not limited to mice, as transgenic rats have also been developed
[28,33–35]. For the most part, transgenic rats overexpressing mutant
SOD1 recapitulatemany features of ALS, includingmotor neuron degen-
eration and axonal loss as well as pathological hallmarks. However there
can be broad variation in the development of phenotypes of certain rat
models [35]. Although transgenic rats are not as widely used as
mice, their larger sizemay offer certain beneﬁts, for example in phar-
macological trials where intrathecal injections or insertion of mini
pumps are required.Transgenic SOD1 rodent models have variable ages of disease onset
and rates of disease progression. Development of ALS-like symptoms in
these mice is now known to be largely dependent upon four factors:
i) SOD1 mutation; ii) transgene expression level; iii) gender and
iv) genetic background [36,37]. In order to rule out the possibility that
the disease phenotype may be the result of overexpression of SOD1
per se, lines of transgenic mice overexpressing the human wildtype
protein have also been created [24,38,39]. It was originally proposed
that wildtype SOD1 did not play a role in ALS, as mice overexpressing
thewildtype protein showed axonopathywithout overtmotor dysfunc-
tion; although signs of abnormal axonal andmitochondrialmorphology
were present from early ages [38,40]. However more recently it has
been emerged that wildtype SOD1 could play a role in ALS pathogenesis
[41–43]. Crucially, overexpression of human wildtype SOD1, at a level
similar to that seen in the SOD1G93A mouse model, can cause progres-
sive motor neuron degeneration [43]. Homozygous expression of a
human wildtype SOD1 transgene resulted in a reduced lifespan, with
a median survival of 367 days, accompanied by slow weight gain
from birth and overt weight loss in older male mice [43]. These mice
also developed an ataxic staggering gait with abnormal hindlimb re-
ﬂexes [43]. Gliosis and misfolded SOD1 were detected in the spinal
cord from 100 days of age, as were signs of vacuolisation and axonal
damage, which are typical of SOD1 overexpression [38,40]. By endstage
around 40% of motor neurons in the thoracic spinal cord had been lost
[43].
Study of numerous SOD1 models has implicated various mecha-
nisms in the pathology of ALS, including mitochondrial dysfunction,
protein misfolding and aggregation, non-cell autonomous insults,
excitotoxicity, oxidative stress and axonal transport (see Fig. 1). Trans-
genic mouse models overexpressing mutant SOD1 have therefore been
central to our understanding the effects of mutant SOD1 and have
formed the basis of much of our knowledge of the underlying patho-
physiology of ALS [44].
3. TDP-43 models of ALS
TDP-43 is a 43 kDa nuclear protein originally discovered because
of its effects on human immunodeﬁciency virus transcription [45]. It
is encoded by the TARDBP gene on chromosome 1, and contains a
nuclear-localisation signal, two RNA-binding motifs, and a glycine-
rich region, which contains a ‘prion-like’ domain and mediates protein
and hnRNP interactions. It is within this glycine-rich domain that the
majority of pathogenic mutations for ALS have been identiﬁed [4,5].
Although the full range of TDP-43 functions remains unclear, it is
known to play crucial roles in alternative splicing and gene expres-
sion [46], embryogenesis [47] and neuronal development [48–50].
However, the effects of pathogenic mutations in TDP-43 on its func-
tion are poorly understood. In vitro and in vivo studies have identiﬁed
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Fig. 1. ALS pathomechanisms and targets tested in recent preclinical trials in rodents.
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including abnormal neuronal function and synaptic defects [51,52],
deleterious effects on mitochondria [53,54] and proteasome dysfunc-
tion [55]. Although it remains unclear how mutations in TARBP cause
ALS, both loss and gain of function mechanisms have been proposed
[56].
Several groups have attempted to model TDP-43-ALS in rodents
and results have shown varied phenotypes, with no TDP-43-ALS
model currently replicating an ALS-like phenotype. Similar to SOD1
rodent models, development of disease phenotypes in TDP-43-ALS
transgenic rodents is highly dependent upon the promoter used and
the level of transgene expression; however these models display
mostly axonal phenotypes with relatively mild motor neuron cell
death. In marked contrast to SOD1 transgenic mice, overexpressionof human wildtype TDP-43 has been shown to cause signiﬁcant
neurodegeneration. Moreover, unlike SOD1 transgenic mice, transgene
expression levels of TDP-43 are typically low and founder lines
which have the highest levels of overexpression show early mortality
preventing the generation of transgenic lines with high levels of
overexpression. The TDP-43 transgenic rodent models generated to
date are summarised in Table 2.
3.1. Knock-out of mouse Tardbp to model ALS
Following the identiﬁcation of ALS causative mutations in TARDBP
[4,5], knock-out mice were developed to determine the effects of
TDP-43 deﬁciency and to establish whether mutations in TARDBP
cause ALS due to a loss-of-function. Independent studies reported
Table 2
Summary of TDP-43 and FUS rodent models. Where possible neuronal loss has been quoted. nd: not described, Y: yes, N: no.
Species Promoter Protein Protein
expression
(fold)
Symptom
onset
(weeks)
Survival
(weeks)
Phenotypes Reference
Abnormal
motor
behaviour
Degeneration Pathology
LMN UMN Cortex Axonal Gliosis cTDP-43/
FUS
CTFs
Mouse Hb9:Cre Motor
neuron
speciﬁc
depletion
0 13 40 Y 60%
loss
nd nd nd Y nd nd Wu et al. [57]
Mouse mPrp TDP-43
A315T
3 13 22 Y 20%
loss
Y nd Y Y Y Y Wegorzewska et al. [58];
Guo et al. [59]
Mouse mPrp TDP-43
WT
1.9 Not affected Xu et al. [60]
Mouse mPrp TDP-43
WT
2.5 2 4–8 Y N nd nd Y Y Y Y Xu et al. [60]
Mouse mPrp TDP-43
M337V
1.9 Not affected Xu et al. [58]
Mouse mPrp TDP-43
M337V
2.5 2 4 Y nd nd nd Y Y Y Y Xu et al. [61]
Mouse mPrp TDP-43
WT
3–4 nd nd N nd nd nd nd Y nd nd Stallings et al. [62]
Mouse mPrp TDP-43
A315T
4 4 37.5 Y nd nd nd nd Y Y Y Stallings et al. [62]
Mouse Thy1.2 TDP-43
WT
Males: 3.6 2-2.5 nd Y N nd nd Y Y N N Shan et al. [54]
Mouse Thy1.2 TDP-43
WT
Females: 1.3 13 nd Y N nd nd nd nd N N Shan et al. [54]
Mouse Thy1.2 TDP-43
WT
1.9 56 nd Y nd nd nd nd nd nd Nd Wils et al. [63]
Mouse Thy1.2 TDP-43
WT
3.8 8 Approx
27
Y 10%
loss
15%
loss
nd nd Y Y nd Wils et al. [63]
Mouse Thy1.2 TDP-43
WT
5.1 2 4 Y 25%
loss
30%
loss
nd nd Y Y Y Wils et al. [63]
Mouse Thy1.2 TDP-25 4.7 nd nd nd nd nd N nd nd Y Y Caccamo et al. [64]
Mouse CaMKII TDP-43
WT
2 8 71 Y nd nd Y nd Y Y Y Tsai et al. [65]
Mouse CaMKII
(TRE)
TDP-43
WT
0.8 (induced
at 4 weeks)
8–49 nd Y nd Y Y nd Y nd nd Igaz et al. [66]
Mouse CaMKII
(TRE)
TDP-43
ΔNLS
7.9 (induced
at 4 weeks)
5 26 Y nd Y Y Y Y Y nd Igaz et al. [66]
Mouse CaMKIIα
(TRE)
TDP-43
WT
3 (induced from P21) nd nd nd nd nd Y nd Y Y nd Cannon et al. [67]
Mouse TDP-43
(BAC)
TDP-43
WT
3 28–32 nd Y nd nd nd N Y nd nd Swarup et al. [68]
Mouse TDP-43
(BAC)
TDP-43
A315T
3 28–32 nd Y nd nd nd N Y Y Y Swarup et al. [65]
Mouse TDP-43
(BAC)
TDP-43
G348C
3 28–32 nd nd nd nd nd N Y Y Y Swarup et al. [68]
Rat TDP-43 TDP-43
WT
nd nd nd nd nd nd nd nd nd Y nd Zhou et al. [69]
Rat TDP-43
(TRE)
TDP-43
M337V
nd (induced on P4) 4.5–4.7 6.5–6.7 Y 17%
loss
Y Y Y Y Y Zhou et al. [69]
Rat NEF
(TRE)
TDP-43
M337V
2 (fully activated by
8.5 weeks)
10 13 Y 20%
loss
nd nd Y nd N Nd Huang et al. [70]
Rat ChAT
(TRE)
TDP-43
M337V
3.5 (fully activated by
8.5 weeks)
9 11 Y 60%
loss
nd nd Y Y N nd Huang et al. [70]
Mouse mPrp FUS
WT
1.4 Not affected Mitchell et al. [71]
Mouse mPrp FUS
WT
1.7 4–5 12 Y 60%
loss
nd nd nd Y Y nd Mitchell et al. [71]
Mouse SBT-rAAV FUS
WT
nd nd nd nd nd nd nd nd nd Y nd Verbeeck et al. [72]
Mouse SBT-rAAV FUS
R521C
nd nd nd nd nd nd nd nd nd Y nd Verbeeck et al. [72]
Mouse SBT-rAAV FUS
Δ14
nd nd nd nd nd nd nd nd Nd Y nd Verbeeck et al. [72]
Rat FUS
(TRE)
FUS WT nd (induced at birth) nd nd nd nd nd Y nd nd nd nd Huang et al. [73]
Rat FUS
(TRE)
FUS
R521C
nd (induced at birth) 5 6 Y nd Nd Y nd Y nd nd Huang et al. [73]
Rat CaMKIIα
(TRE)
FUS
R521C
nd (induced from
30 days)
9 18 nd nd nd Y nd Y Y nd Huang et al. [74]
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in early embryonic lethality or death of embryonic stem cells, thereby
identifying an essential role for TDP-43 in development [47,75–77].However, disruption of one Tardbp allele did not affect either protein
or mRNA levels, suggesting an autoregulation of TDP-43 levels
[47,76,77]. One report characterised a cohort of Tardbp+/− mice and
1425P. McGoldrick et al. / Biochimica et Biophysica Acta 1832 (2013) 1421–1436observed age-dependent deﬁcits in grip strength and cage-hanging
tests compared to wildtype littermates [76].
An alternative approach to examine the effects of reduced TDP-43
expression is to use a conditional knock-out strategy. Chiang and
colleagues [75] found that heterozygous deletion of Tardbp did not
alter TDP-43 protein or mRNA levels; however conditional deletion of
both Tardbp alleles in adult mice caused rapid loss of body fat and
death within 9 days. Interestingly, the loss of body fat was associated
with a downregulation of Tbc1d1, a protein linked with obesity [75].
However, these rapid and severe effects likely preclude any investiga-
tion of loss of TDP-43 with regard to motor neuron degeneration.
More recently, the effect of a loss of TDP-43 function has been
investigated by depleting TDP-43 from Hb9-positive spinal cord motor
neurons in mice [57]. This targeted depletion of TDP-43 resulted in
signiﬁcantly reduced bodyweight of mice at 8 weeks of age, with
rotarod deﬁcits apparent by 15 weeks, followed by abnormal hindlimb
clasping and kyphosis. The authors noted that although TDP-43 protein
levels in the spinal cords of knock-out mice were not altered, likely due
to the relatively small proportion of cells which are Hb9-positive,
choline acetyltransferase (ChAT) levels were signiﬁcantly reduced by
20 weeks of age. A reduction in ChAT levels correlated with a signiﬁ-
cant, progressive loss of ChAT-positive spinal cord motor neurons,
with evidence of a speciﬁc vulnerability of larger motor neurons. In
addition, motor neuron loss was accompanied by age-dependent gliosis
and cytoplasmic aggregation of ubiquitin in motor neurons lacking TDP-
43. Development of phenotypes in thesemice showed a sex-bias towards
males, with average lifespan approximately 10 months of age [57].
3.2. Transgenic TDP-43 models using the mouse prion promoter
The mouse Prion promoter (mPrp) has been used by several groups
to express transgenes in the central nervous system (CNS) [78]. One
group has reported that expression of human wildtype TDP-43 at
3-4-fold greater levels than endogenous TDP-43 did not result in any
deleterious effects other than mild gliosis and ubiquitin aggregation
within the spinal cord [62]. However, a conﬂicting report observed that
increasing levels of human wildtype TDP-43 from 1.9-fold to 2.5-fold
above endogenous levels, resulted in neurodegeneration and reduced
life span to between 4 and 8 weeks [60]. Although these mice lacked
lower motor neuron loss, axonal degeneration was evident, alongside
pathological hallmarks of TDP-43 proteinopathies [60]. Xu and colleagues
[61] subsequently reported similar ﬁndings with mutant M337V
TDP-43 transgenicmice [61]. Thesemicewere unaffectedwhenmutant
TDP-43 levels were increased by 1.9-fold of endogenous levels, but
presented a similar phenotype to wildtype overexpressors when ex-
pression was increased to 2.5-fold of endogenous levels, albeit lifespan
was reduced to 4 weeks of age [61].
Indeed, the ﬁrst published transgenic TDP-43 mouse model
reported the toxic properties of the A315T mutation under control
of the mPrp [58]. At 3-fold levels of the endogenous protein, mutant
TDP-43 caused the development of an abnormal gait by 13 weeks of
age and paralysis and death by 22 weeks of age [58]. This phenotype
was accompanied by a loss of upper motor neurons but a relatively
mild loss of lower motor neurons, with signs of axonal degeneration.
However, subsequent analysis of these mice revealed signiﬁcant
intestinal dysfunction causing decreased food intake, which is likely to
be the cause of their early mortality [59]. A slightly more severe pheno-
type was observed when the mutant A315T TDP-43 was expressed at
incrementally higher levels than wildtype TDP-43 overexpressing
mice [62], with mice showing motor dysfunction, skeletal muscle
denervation and early mortality [62].
3.3. Transgenic TDP-43 models using the mouse Thy1.2 promoter
Several groups have used the Thy1.2 promoter to produce transgenic
mice overexpressing human TDP-43 [54,63,64]. This promoter drivesthe expression of transgenes in neuronal cells from one week of age,
and therefore avoids the deleterious effects of TDP-43 overexpression
during development. Expression of wildtype TDP-43 in one transgenic
line showed marked sexual dimorphism [54]. Female mice expressed
wildtype TDP-43 at 1.9 fold levels higher than endogenous TDP-43,
which resulted in nophenotype other thanmild tremor [54]. In contrast,
malemice of the same line expressedwildtype TDP-43 at 3.6-fold great-
er than endogenous levels, and developed tremor, abnormal hindlimb
reﬂexes and altered gait by 2 weeks of age, with a decrease in
bodyweight detected at 4 weeks of age [54]. Interestingly, motor
neurons of these mice showed abnormal cytoplasmic aggregations
containing mitochondrial markers. In addition, reduced axonal trafﬁck-
ing of mitochondria to nerve terminals and abnormal neuromuscular
junction (NMJ) morphology were also observed [54]. As these mice
had a similar phenotype to mice which model spinal muscular atrophy
(SMA), the authors examined Gemini of coiled bodies (GEMs), which
contain the Survival of Motor Neuron protein, a deﬁciency of which
causes SMA. The distribution of GEMs in motor neuron nuclei was
disrupted by TDP-43 overexpression and an increased number of
GEMS was observed [54]. To determine whether this was due to a
loss or gain of function, the conditional knock-out mouse described
above [75] was used, and showed that TDP-43 deﬁciency prevented
nuclear GEM formation [54], demonstrating that TDP-43 is critical
for nuclear GEM formation, and has may be involved in RNA splicing.
Moreover, investigation into the transcription-proﬁle of these trans-
genic mice revealed differential expression of numerous genes,
including neuroﬁlament proteins, which were associated with a
reduction in axon calibre [54].
The dose-dependent toxicity which has been described for wildtype
TDP-43 in models using the mPrp [60] has also been described when
using the Thy1.2 promoter. One group characterised three lines of
mice with varying expression of human wildtype TDP-43: i) a low-
expressing line with a 1-fold increase in TDP-43 levels compared to
non-transgenic mice, ii) an intermediate-expressing line with a 3.8
fold increase in TDP-43 levels and iii) a high-expressing line with a
5-fold increase in TDP-43 levels [63]. In the lowest expressing line,
minor motor dysfunction was observed at 15 months, although there
was no effect on lifespan [63]. However, in the intermediate- (ii) and
high-expressing (iii) lines, the onset of motor dysfunction occurred
earlier, at 4 months and 18 days, and death at 6.7 months and before
30 days of age, respectively [63]. These two lines exhibited dose-
dependent neuronal death of both upper and lower motor neurons,
with the higher-expressing line showing a 25% loss of lowermotor neu-
rons at end-stage [63]. Moreover, both lines recapitulated some aspects
of TDP-43 proteinopathies, as neuronal cytoplasmic inclusions and neu-
ronal intranuclear inclusions were observed in layer V of the anterior
cortex [63].
As C-terminal fragments of TDP-43 have been shown to be accu-
mulated in motor neurons of post mortem tissue from of ALS patients
[3], a transgenic mouse line was developed which overexpressed the
C-terminal 25 kDa form of TDP-43 at 4.7-fold levels greater than the
endogenous full-length protein [64]. These mice did not develop an
overt phenotype, although an age-dependent increase in TDP-43 C-
terminal fragments and cognitive impairments were observed from
26 weeks of age [64].
3.4. Transgenic TDP-43 models using the CaMKII promoter
The CaMKII promoter limits expression to the forebrain. Using the
CaMKII promoter, one group expressed wildtype mouse TDP-43 at
2-fold levels greater than endogenous TDP-43 and observed cognitive
decline from 8 weeks of age, and deﬁcits in long-term potentiation of
hippocampal neurons [65]. These mice showed abnormal hindlimb
reﬂexes, impaired rotarod performance and reduced grip strength
by 26 weeks of age, at which point there was a 26% loss of
cortical neurons and signiﬁcant cortical atrophy [65]. More recent
1426 P. McGoldrick et al. / Biochimica et Biophysica Acta 1832 (2013) 1421–1436examination of these mice has shown that rapamycin, an activator of
autophagy and an immunosuppressant, rescued the learning and
memory impairments and crucially, also alleviated motor decline, in-
dependent of any effect on spinal cord motor neurons, as would be
expected with the CaMKII promoter [79]. These positive effects on be-
haviour were associated with a reduction in neuronal apoptosis and
decreased incidence of TDP-43 pathology in forebrain neurons, lead-
ing this group to suggest that the beneﬁcial effects of rapamycin
were associated with increased autophagy and decreased activation
of the mTOR pathway [79].
Using the CaMKII promoter and the tetracycline response element
system (TRE) to control transgene expression, another group created
a line of human wildtype TDP-43 transgenic mice, and a line which
overexpressed wildtype TDP-43 lacking its nuclear localisation signal
(NLS; TDP-43ΔNLS), in order to investigate the effects of cytoplasmic
localisation of TDP-43 [66]. In both lines, transgene expression was
activated 4 weeks after birth. Mice overexpressing wildtype TDP-43
showed a 0.8-fold increase in protein levels compared to endogenous
TDP-43 and developed an abnormal hindlimb clasp between 4 and
12 weeks after induction. During the same time, progressive neuronal
loss was evident in the dentate gyrus, from a 25% loss of neurons from
4 weeks after induction to a 75% loss after 12 weeks [66]. Expression of
the TDP-43ΔNLS protein was 7.9-fold higher than the full-length en-
dogenous protein [66]. These mice hadmuch higher levels of transgene
expression and displayed an accelerated progression of phenotypes,
with the development of hindlimb clasping 1 week after the induction
of transgene expression [66]. Cortical neuron loss was severe, with a
50% loss 4 weeks after induction, accompanied, as expected, by cyto-
plasmic localisation of TDP-43ΔNLS [66]. As has been described in
selected TDP-43 models, some degeneration of corticospinal tract
axons was also observed [66].
Another group has also used the CaMKII promoter and conditional
expression of human wildtype TDP-43 [67]. Overexpression of full-
length human wildtype TDP-43 in the forebrain of mice during devel-
opment resulted in dose-dependent cortical atrophy and extensive
neuron loss, particularly in the hippocampus [67]. Overexpression of
wildtype TDP-43 at 2-fold levels greater than endogenous TDP-43
resulted in 80% survival of mice at 2 months of age, whereas
overexpression of TDP-43 at 3-fold levels higher than endogenous
TDP-43 resulted in much greater mortality, with only 30% of mice sur-
viving at 2 months of age. In both lines, forebrain pathologywasmarked
andneuronal losswas accompanied by cytoplasmic aggregation ofmito-
chondria and phosphorylated TDP-43, cytoplasmic ubiquitin localisation
and gliosis [67]. The authors suggested that moderate overexpression of
TDP-43 in the developing forebrainwas toxic to neurons [67]. In support
of this possibility, induction of transgene expression from 21 days of age
did not result in any behavioural phenotype up to 12 months of age.
However, cortical atrophy and pathology were evident, albeit in the ab-
sence of mitochondrial aggregation, leading the authors to suggest that
abnormal cytoplasmic aggregation of mitochondria was a developmen-
tal effect, and that induction of transgene expression from21 days of age
resulted in pathological hallmarks of TDP-43 proteinopathies [67]. Sim-
ilar effects were observed when transgene expression was induced at
10 months of age [67].
3.5. TDP-43 models using a bacterial artiﬁcial chromosome
Using a bacterial artiﬁcial chromosome (BAC) and the endogenous
promoter, lines of mice have beenmade expressing genomic fragments
of human wildtype and mutant A315T or G348C TDP-43 [68]. The
expression of the mutant TDP-43 in these mice was approximately 3-
fold greater than endogenous TDP-43 levels for all wildtype and mutant
TDP-43 lines. In all lines this resulted in a signiﬁcant downregulation of
endogenous TDP-43 levels, between 3 and 10 months of age [68]. Mice
overexpressing wildtype TDP-43 displayed cognitive impairments from
26 weeks of age and motor dysfunction from 42 weeks of age, whichwere also observed in both mutant lines [68]. These lines also all
displayed a decrease in the number of large calibre axons and an increase
in the number of small calibre axons, independent of axonal loss [68].
Moreover, peripherin aggregates, which are considered a marker of ALS
pathology [68], were observed in cortical and motor neurons. In the
mutant G348C TDP-43 line, minor denervation of skeletal muscles
was observed, together with a decrease in the levels of neuroﬁlament
proteins, perhaps suggesting that this was the more toxic of the two
mutant lines [68].
3.6. Transgenic TDP-43 rat models
In addition to mouse models, several rat models of TDP-43-ALS
have also been developed [69,70]. Constitutive expression of mutant
M337V TDP-43, but not wildtype TDP-43, in founder lines caused
early mortality and prevented the generation of further lines [69]. In
contrast to the effects of mutant TDP-43, no deleterious effects of
wildtype TDP-43 were reported, aside from an increase in phosphory-
lated cytoplasmic TDP-43 levels [69]. In order to produce mutant
TDP-43 lines, the authors used the TRE system to induce transgene
expression ofmutantM337V TDP-43 on postnatal day 4, which resulted
in rotarod deﬁcits by 4.5 weeks of age and rapidly led to paralysis by
approximately 7 weeks of age. The effect on the motor system of
these mice was robust, with a 17% loss of lower motor neurons, accom-
panied by the degeneration of large calibre axons in the ventral roots
and corticospinal tract, with evidence of the denervation and atrophy
of skeletal muscles [69]. By the time of paralysis, neuronal loss was
also observed in the cortex, hippocampus and cerebellum. Pathologically,
lower motor neurons lacked TDP-43 inclusions; although they were
identiﬁed in cortical neurons [69].
A more recent study focussed on the inducible expression of mutant
M337V TDP-43 in rats using two different promoters: neuroﬁlament
heavy chain (NEF) promoter and the choline acetyltransferase (ChAT)
promoter [70]. Using the NEF promoter, mutant TDP-43 expression
was fully activated by 8.5 weeks of age. Between 10 and 12 weeks of
age rats began to lose grip strength and mobility, and developed
hindlimb paralysis by 13 weeks of age. At the time of paralysis,
degenerating axonswere observed with signs of skeletal muscle dener-
vation and atrophy, and a 20% loss of both dentate gyrus and lower
motor neurons was observed, albeit in the absence of any typical path-
ological markers [70]. Characterisation of a line of rats expressing
mutant M337V TDP-43 under the control of the ChAT promoter,
which drives expression in motor neurons, revealed more severe
degeneration. Full activation of the transgene by 8.5 weeks of age was
rapidly followed by a loss of grip strength and reduction in mobility
within one week. After only 1.5 weeks of transgene expression, paraly-
sis was observed. Similar to theM337Vmutantmice using the NEF pro-
moter, there was evidence of degenerating axons and both denervation
and atrophyof skeletalmuscles, however therewas signiﬁcantly greater
motor neuron degeneration, with a 60% reduction in the number of
lower motor neurons, with those which survived showing cytoplasmic
aggregation of ubiquitin [70].
3.7. Non-human primate TDP-43 model
Only one non-human primate (NHP)model of TDP-43-ALS has been
reported to date, developed using viral expression [80]. Althoughwide-
spread use of NHPmodels of ALS is unlikely due to the ethical and logis-
tical issues that surround their use, because of the similarities of their
motor system and that of humans, NHPs may be particularly useful for
understanding degenerative processes. Flag-tagged human wildtype
TDP-43 in an adeno-associated virus (AAV) 1 vectorwas injected directly
into the side of the dominant hand of the cervical spinal cord of adult
cynomolgus monkeys [80]. The AAV used in this study has a preference
for infecting terminally differentiated cells, and tagged TDP-43 was
only observed in motor neurons [80]. Injection of TDP-43 AAV1 into
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proximately 20-fold greater than endogenous TDP-43 mRNA, which
resulted in progressive muscle weakness and atrophy on the injected
side, leading to paralysis, with some contralateral involvement [80]. At
a late-stage of dysfunction in these NHPs tagged TDP-43 was observed
in the cytoplasm of motor neurons and was occasionally aggregated
and accompanied by a loss of endogenous TDP-43 from the nucleus
[80]. Moreover, abnormal cytoplasmic accumulations of phosphorylated
neuroﬁlaments andperipherinwere observed, furthermimicking the pa-
thology seen in ALS patients [80]. However, cytoplasmic TDP-43 was at
its highest levels in early stages in degenerating neurons, which
contrasted to pathological ﬁndings in patient tissue [80]. Crucially, unlike
most rodent TDP-43models, signiﬁcantmotor neuron degenerationwas
observed (50% loss), accompanied by loss of large axons [80]. Degenera-
tion was proposed to be independent of the presence of C-terminal frag-
ments of TDP-43, which were not detected [80].
To investigate whether these effects were species-speciﬁc, an
identical TDP-43-AAV1 was injected into the cervical spinal cord of
adult rats [80]. Rats had similar expression of TDP-43 to the injected
NHPs and also showed progressive muscle weakness and atrophy
[80]. However, injected rats failed to recreate cytoplasmic localisation
of TDP-43 or other neuropathological ﬁndings observed in NHPs,
suggesting that the NHPs more accurately recapitulated TDP-43-ALS
pathology [80]. Although these results suggest that there may be
species-speciﬁc differences between rodents and NHPs, with respect
to TDP-43 pathology, the use of NHPs to model ALS, or other neurode-
generative disorders is limited, due to ethical considerations, size,
cost, lifespan and the reduced options of genetic manipulation. As
such, rodents remain the favoured model organisms for ALS modelling,
although it is important to recognise the limitations of such models,
especially with respect to the development of the motor system and
potential species differences [81].
4. FUS models of ALS
FUS was originally identiﬁed due to its oncogenic properties
following a chromosomal translocation resulting in the fusion of a
truncated FUS protein with the transcription factor CHOP [82,83]. The
FUS gene is located at 16p11.2 and comprises 15 exons encoding a
multifunctional 526 amino-acid protein [84] with a complex domain
structure. The N-terminus contains a Gln-Gly-Ser-Tyr-rich domain and
glycine rich domain, and is proposed to have ‘prion-like’ properties [85].
Adjacent to this domain is an RNA recognition motif (RRM) domain,
which contains a nuclear export sequence (NES), followed by two
Arg-Gly-Gly domains which ﬂank a zinc-ﬁnger region. The C-terminus
of the protein contains a non-classical nuclear localisation signal
(NLS), which is recognised by transportin [86]. FUS is expressed ubiqui-
tously in all cells, although some rodent data suggests that expression
outside the CNS decreases with age, and is absent from skeletal muscle,
liver and kidney inmice from 80 days [87]. FUS binds DNA and RNA and
primarily shows nuclear localisation, dependent upon the C-terminal
motif [88,89].
Mutations in FUS are causative for a similar proportion of FALS cases
(FUS–ALS) as TARDBPmutations; however it has been suggested that it
may function downstream of TDP-43 and in parallel with other RNA-
binding proteins [90]. Developing models of FUS-linked dysfunction is
important to understanding mechanisms by which mutations in FUS
cause ALS and the mechanism by which aberrant RNA metabolism
may cause neurodegeneration.
4.1. Knock-out of Fus
Prior to the identiﬁcation of ALS-causing mutations in FUS, knock-
out mice were produced in order to investigate the effects of FUS de-
ﬁciency [91]. On an inbred C57BL/6 background, despite normal in
utero development, Fus null mice failed to thrive and died within16 h of birth, exhibiting abnormal lymphocytes and chromosomal
instability [91]. In contrast, when Fuswas ablated on a partially outbred
background (CD1 with 129/SvEv) there were no lethal perinatal effects
[92]. Rather, knock-out of Fus in outbred mice results in the generation
of smaller mice at birth, reduced weight gain post-weaning, sterility in
males and reduced fertility in females [92]. Molecularly, knock-out of
Fus enhances sensitivity to irradiation and causes chromosomal insta-
bility [92].
4.2. FUS models of ALS
To date, there are only four published accounts of transgenic
rodent lines overexpressing FUS: i) transgenic mice which overexpress
HA-tagged human wildtype FUS under control of the mouse prion
promoter [71]; ii) somatic brain transgenic (SBT) mice expressing
V5-tagged human wildtype FUS, mutant R521C and FUS lacking its
nuclear localisation signal (Δ14) [72]; iii) transgenic rats which condi-
tionally express human wildtype or mutant FUS under a TRE [73]; and
iv) transgenic rats which express mutant FUS under the CaMKIIα pro-
moter with a TRE [74] (Table 2).
Overexpression of HA-tagged human wildtype FUS under the
control of a modiﬁed mouse prion promoter has been shown to
cause an aggressive neurodegenerative phenotype in homozygous
mice, although hemizygous mice are unaffected [71]. In hemizygous
mice, total FUS protein levels were approximately 1.4-fold higher
than non-transgenic animals and in homozygous mice, this was
increased to approximately 1.7-fold and was associated with a signif-
icant downregulation of endogenous mouse FUS. Nuclear FUS levels
were signiﬁcantly increased in both hemizygous and homozygous
mice, however homozygous mice also showed a signiﬁcant increase in
cytoplasmic FUS levels. Despite relatively minor differences in total
FUS levels and subcellular localisation, hemizygous mice displayed no
cellular pathology or motor dysfunction, whereas homozygous mice
displayed FUS-positive, ubiquitin-negative cytoplasmic inclusions in
surviving motor neurons of the spinal cord, and signs of gliosis. Cyto-
plasmic FUS inclusions were also observed in cortical neurons of these
mice, in the absence of neuronal loss and gliosis. In marked contrast to
the transgenic rat overexpressing human wildtype FUS [73], homozy-
gous mice in this study showed severe motor dysfunction and required
euthanasia at approximately 12 weeks of age, by which point they
showed a 60% loss of lower motor neurons [71].
In somatic brain transgenic (SBT) mice, recombinant adeno-
associated virus has been used to express V5-tagged human wildtype
or mutant (R521 or Δ14) FUS postnatally in neuronal cells of the
mouse brain [72]. Although these mice do not model ALS, this study
showed that mutant, but not wildtype, FUS had aberrant subcellular
localisation, the extent of which was mutation dependent and corre-
lated with the clinical severity of the mutations in patients: the Δ14
mice had increased cytoplasmic localisation and patients with this
mutation have an early-onset of disease with rapid progression [72].
Crucially, although there was no neuronal death, neuronal cytoplasmic
inclusions similar to those seen in post mortem ALS tissue were
observed in cortical neurons.
The transgenic rat model of FUS–ALS had controlled over-
expression of human wildtype and mutant R521C FUS, with
approximately 20 copies of the transgene [73], using the samepromoter
system as a transgenic TDP-43 rat [69]. Interestingly, there was a
contrast in the phenotypes of the wildtype and mutant FUS over-
expressors. Overexpression of mutant FUS from weaning caused rapid,
progressive paralysis requiring euthanasia at 10 weeks, accompanied
by axonopathy, skeletal muscle denervation and loss of cortical and
hippocampal neurons. However these rats had only a minor loss of
spinal motor neurons, suggesting that paralysis was the result of
axonopathy [73]. Mutant FUS displayed very little cytoplasmic staining
and FUS was absent from ubiquitinated aggregates in degenerating
cells, although selected mitochondrial proteins co-localised with
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but is also commonly seen in TDP-43 transgenic mice [73]. Gliosis was
also present [73]. In contrast, at the same age, rats overexpressing
human wildtype FUS had nomotor phenotype, but developed memory
deﬁcits, degeneration of cortical and hippocampal neurons, ubiquitin
aggregation and gliosis at one year of age, demonstrating an
FTLD-U-like phenotype [73]. The similarities and differences between
the overexpression of wildtype and mutant FUS in these rats could
perhaps suggest different pathomechanisms in ALS and FTLD that result
from dysfunction of the same protein.
Controlled expression of the mutant R521C transgene in rats,
under the CaMKII promoter and using TRE, from 30 days of age,
resulted in impaired spatial learning and memory by 5 weeks of age
[74]. This deﬁcit was associated with signiﬁcant loss of neurons in the
dentate gyrus and frontal cortex by 8–9 weeks of age. Neuronal loss in
these areas was also associated with abnormal neuritic branching,
altered dendritic spine density and progressive golgi fragmentation
[74]. Pathologically, FUS and ubiquitin-positive aggregates were
observed in the cytoplasm of neurons, however there was no co-
localisation and neurons of the entorhinal cortex were suggested to be
prominent sites of cytoplasmic FUS localisation [74]. Similarly to the
previous study, there was evidence of cytoplasmic aggregation of
mitochondria in degenerating neurons [74]. The authors noted that
treatment with Rosiglitazone, a peroxisome proliferator-activated
receptor gamma, could rescue spatial memory deﬁcits in these rats
[74]. Thiswas proposed to be independent of neuronal loss and resulted
from the prevention of abnormal dendritic development [74].
5. VCP models of ALS
Identiﬁcation of mutations in valosin-containing-protein (VCP) as
causative for ALS [11] and Inclusion Body Myositis with Paget's
disease of bone and frontotemporal lobar degeneration (IBMPFD) [93]
has led to the recent development of mouse models of these diseases
[94,95]. VCP is an AAA-ATPase which has a range of cellular functions
[96,97]. Similarly to Tardbp, homozygous ablation of the Vcp gene in
mice causes early embryonic lethality [98]. The varying effects of VCP
mutations make the use of animal models to solely model one aspect
challenging, however it is important to understand the mechanisms
by which mutations in VCP cause motor neuron degeneration.
Knock-in mice expressing human mutant VCP have been used to
investigate IBMPFD [94]. Recent reports have also examined whether
knock-in of the R155H mutation in VCP, which causes ALS [11], could
cause motor neuron degeneration in heterozygosity or homozygosity
[99,100]. In heterozygote knock-in mice, the R155H mutation in VCP
did not affect lifespan [99]. However, thesemice developed progressive
weakness from 9 months of age and showed signiﬁcant weight loss by
24 months of age [99]. Survival of spinal cord motor neurons was
unaffected at 8 months of age; however by 20 months of age approxi-
mately 50% of motor neurons had been lost. Consistent with this
motor neuron degeneration, electromyography (EMG) of hindlimb
muscles at 24 months of age showed evidence of denervation and
neurogenic changes [99]. Pathological analysis of the spinal cord
revealed gliosis, oxidative stress and cytoplasmic accumulation of mito-
chondria in motor neurons [99]. Age-dependent aggregation of TDP-43
in the cytoplasm of motor neurons was noted, and these aggregates
were ubiquitin-positive and colocalised with aggregated mitochondria
[99]. Interestingly, this group reported that TDP-43 protein levels in
the spinal cord were increased at 18 months of age [99].
Compared to the heterozygous knock-in mice, homozygous
expression of human mutant VCP resulted in a much more aggressive
phenotype, with early lethality and very few pups surviving to 21 days
of age [100]. These mice were born at a reduced Mendelian ratio and
were small from birth. EMG studies revealed myopathic processes in
hindlimbmuscles, with abnormal motor units, although no ﬁbrillisation
or fasciculation were observed. Histopathological examination ofhindlimb muscles showed evidence of neurogenic changes, resulting
from denervation and subsequent reinnervation. Signs of impaired
autophagy were detected in brain and muscle tissue, in addition to the
aggregation of mitochondrial proteins. Morphological assessment of
spinal cord motor neurons showed abnormalities as early as 10 days
of age. Motor neuron survival was not quantiﬁed, however cytoplasmic
aggregation of TDP-43was noted [100]. Althoughmutations in VCP have
complex effects, and phenotypes in transgenic mice may not be solely
due to motor neuron degeneration, study of VCP models has clearly
shown the deleterious effects of mutant VCP on motor neuron survival.
6. What has been learnt from new rodent models of ALS?
Our knowledge of the genetics of FALS has grown over recent
years, which has resulted in the development of a number of new
rodent models of disease. Many recent studies have described new
models using TDP-43, FUS and VCP; however in large part these models
donot recapitulate ALS-likephenotypes to the extent of SOD1 transgenic
mice.
Several TDP-43 transgenic mice have been produced with varying
phenotypes. Behaviourally, nearly all TDP-43 models show motor
dysfunction, progressive gait abnormalities and hindlimb clasping,
which are accompanied by signiﬁcant weight loss or paralysis.
Despite motor dysfunction and post mortem observations of gliosis
and other pathological characteristics of ALS, the loss of lower motor
neurons is usually mild. However, axonal degeneration and the dener-
vation and atrophy of skeletal muscle are commonly observed in
these models. Whether this is a result of a preferential TDP-43-
mediated toxicity for cortical neurons and axons is unclear. However,
it is possible that the axonal degeneration often observed in these
models results in mortality before extensive motor neuron loss.
The variation in the severity and development of deleterious
effects of mutant TDP-43 is likely to be due to a combination of the
differences in choice of promoter, gender, level and timing of trans-
gene expression and type of protein. However, there may also be con-
founds associated with the downregulation of endogenous mouse
TDP-43 [61,66,68]. These ﬁndings are in marked contrast to mice that
model mutant SOD1–ALS. For example, the overexpression of wildtype
TDP-43 is highly toxic, as is knock-out of the Tardbp gene, and TDP-43
protein levels are tightly controlled. It has been suggested that a
loss of function and/or gain of function mechanism could underlie mu-
tant TDP-43-mediated neurodegeneration [56]. Rodent models over-
expressing wildtype or mutant TDP-43 have consistently shown dose-
dependent toxicity, and conversely, loss of TDP-43 function in adult
mice has revealed lethal effects on metabolism. Intriguingly, both
overexpression and depletion of TDP-43 have been shown to affect
formation of GEMS, potentially disrupting downstream RNA splicing.
Although it remains unclear by which mechanism mutant TDP-43
causes neurodegeneration, the toxicity observed in rodent models of
TDP-43 does not correlate with cytoplasmic aggregation of the protein,
suggesting that this is not a critical pathological process [56]. Intriguingly,
a feature common to TDP-43, FUS and VCP models is the cytoplasmic
aggregation of mitochondrial proteins.
Few studies modelling FUS or VCP–ALS in rodents have been pub-
lished to date. FUS models of ALS have shown variable toxicity of the
human wildtype protein when overexpressed [71,73]. Similarly,
overexpression of mutant FUS causes signiﬁcant cortical neuron degen-
eration, axonopathy and skeletal muscle denervation in transgenic rats,
with only mild loss of spinal cord motor neurons [73]. In contrast,
overexpression of human wildtype FUS in transgenic mice caused
severe degeneration of spinal cord motor neurons [71]. Knock-out of
Fus in mice does not cause embryonic lethality as knock-out of Tardbp
or Vcp do, nor has loss of FUS been associated with neuronal loss or
motor dysfunction, potentially suggesting that the deleterious effects
of mutant FUS are not, at least, solely due to a loss-of-function. Howev-
er, as FUS is proposed to act downstream of TDP-43 [90], it is possible
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mice. Consistent with in vitro studies which correlated the extent of
cytoplasmic FUS localisation with cellular toxicity and clinical pheno-
type [86,88,101,102], neuronal loss and dysfunction in FUS models
have also been linked to cytoplasmic localisation [71,74].
The use of transgenic mice expressing mutant VCP is more limited
than that of TDP-43 or FUS, due to the widespread and complex
symptoms associated with mutations in VCP. Nevertheless, as recent
publications have shown, expression of mutant VCP in mice can cause
motor neuron degeneration and these mice model several aspects of
ALS, including motor neuron degeneration, denervation and atrophy
of skeletal muscle and cytoplasmic aggregation of TDP-43 [99,100].
Knock-out of Vcp inmice is embryonically lethal [98], and as fewmodels
have beenmade, little is known about the pathological effects ofmutant
VCP. However, evidence frompublished reports [99,100] has implicated
impaired autophagic processes in disease pathogenesis.
7. The use of rodent models of ALS to investigate pathomechanisms
of ALS and trial new therapeutics
Examination of animal models, in vitro systems and post mortem
patient tissue has implicated a wide variety of pathomechanisms in
ALS, including dysregulation of proteostasis, abnormal mitochondrial
function, non-autonomous cell death, inﬂammation, deﬁcient axonal
transport and oxidative stress [103] (Fig. 1). Rodent models of ALS,
in particular mutant SOD1 mice, have been used extensively, not
only to investigate the underlying pathomechanisms of ALS, but to
also test new therapeutics. Despite the successes of rodent models in
elucidating the underlying pathophysiology of ALS, and the intensive
testing of a wide variety of compounds that target these various patho-
logical mechanisms, riluzole remains the only treatment licensed for
the treatment of ALS.
Fig. 1 and Table 3 describe published data from 2009 to date, of
studies which have assessed the efﬁcacy of a variety of treatments
in rodent models of ALS. This table is limited to pharmacological
interventions and omits studies examining the effects of genetic
modiﬁcation (knock-out or overexpression), or the use of exogenous
cells (including stem cells). As Fig. 1 shows, a large number of
pathomechanisms have been targeted in ALS models, which will be
brieﬂy discussed.
Mitochondria have been considered an important therapeutic
target, due to both their importance in cellular function and survival,
as well as their association with other pathomechanisms such as
oxidative stress and intracellular calcium/excitotoxicity. Evidence
from patient tissue and animal models has shown abnormalities in
respiratory chain activity, mitochondrial morphology and protein
import, amongst other facets of mitochondrial function [175–179]. An
example of a therapeutic targeting mitochondria and oxidative stress
is dexpramipexole. Despite beneﬁcial effects in the SOD1G93A mouse
model [180] and early signs of promising effects in patients [181], a
recently completed phase III trial failed to show any beneﬁt and has
been discontinued [182].
Protein misfolding and aggregation are key pathomechanisms
which are attractive targets due to the range of deleterious effects
which can arise downstream from misfolded or aggregated proteins.
For example, evidence has shown that misfolded wildtype or mutant
monomeric SOD1 has toxic properties affecting axonal transport [41]
and moreover, evidence suggests that misfolded mutant SOD1 can dis-
rupt mitochondrial function [183]. Cytoplasmic aggregation of proteins
is a characteristic pathological feature of ALS and although some contro-
versy remains as to whether it is a primary toxic effect or not, neverthe-
less, preventing or reducing protein misfolding and aggregation
presents an opportunity to affect disease course.
In view of the non-cell autonomous and inﬂammatory nature of ALS,
targeting of pathomechanisms in non-neuronal cells has been an in-
creasingly attractive possibility. Activation of astrocytes and microgliais observed in the CNS of animal models of ALS, and mitochondrial
dysfunction, oxidative stress, excitotoxicity and protein misfolding are
all proposed to contribute to the non-cell autonomous degeneration
of motor neurons [184–186] and the observed inﬂammation [187–189].
Despite the role of non-neuronal cells in ALS progression, clinical
trials of compounds proposed to modulate these pathways have
failed to produce beneﬁcial effects in ALS patients. Indeed, a phase
III trial of minocycline reported harmful effects on ALS patients
[190], as did a phase II trial of thalidomide, in the absence of any
functional improvement [191].
Reducing glutamatergic input onto motor neurons, and therefore
calcium inﬂux and excitotoxic stress, has also been targeted as a
potential therapeutic in ALS. The importance of this pathway is evident
from the efﬁcacy of riluzole, the only licensed therapeutic for ALS,which
is known to have antagonistic effects on glutamatergic transmission,
amongst other effects [192–194]. Together with the ﬁndings of reduced
levels of astrocytic glutamate transport proteins in ALS patients
[195,196], targeting of this pathomechanism is a rational approach
for the development of an ALS therapeutic. However, attempts to
reduce excitotoxicity with a number of agents including ceftriaxone,
memantine and talampanel, have failed to progress beyond phase II/III
trials, as primary outcomemeasures have not been reached [197–199].
A number of studies have examined the possibility that neuronal
function and survival may be enhanced by strategies that aim to
increase neurotrophin levels. Despite promising results from rodent
models, these treatments have not translated into the clinic either,
for example, a phase III trial of IGF-1 failed to provide any beneﬁt in
ALS patients [200].
Although many pathomechanisms have been targeted in both
pre-clinical and clinical trials of ALS, all of which have failed to produce
any signiﬁcant beneﬁt in ALS patients, very few, if any, have targeted
axonal transport or RNA processing. Defects in axonal transport have
been identiﬁed in both animal models and ALS patients [201] and in
fact precede the development of ALS-like symptoms in the SOD1G93A
model [202]. As with other pathomechanisms, defects in axonal trans-
port are interlinked, and can also be associated with abnormal mito-
chondrial function and transport of neurotrophic factors. Rescuing
axonal transport deﬁcits in SOD1 models, through crossing to mice
carryingmutations in dynein, has been shown to confer some beneﬁcial
effects in selected SOD1 models, although this may be partly due to
reduced excitotoxic insult [203,204]. There has been little therapeutic
progress in this direction, as speciﬁc pharmacological modiﬁers of axo-
nal transport have not yet been identiﬁed. As RNA processing has only
recently been strongly associated with ALS, and there is limited evi-
dence for altered RNA processing in SOD1 models, manipulation of
RNA processing is not yet a viable therapeutic strategy. However, as
hexanucleotide repeat expansions in C9ORF72 are suggested to cause
ALS/FTLD, at least in part, through an RNA gain-of-function [15],
advances in therapeutics for myotonic dystrophy, such as siRNA and
antisense oligonucleotide treatments [205,206], could be extremely
informative for those working in the ﬁeld of ALS.
As shown in Table 3, many therapeutic approaches in ALS models
have resulted in marginal disease modifying effects, including delaying
disease onset and extending survival, however, these are often
interlinked. In many studies, agents have been tested in mouse models
presymptomatically, which is of limited translational value as the
majority of ALS cases are sporadic and patients are only treated after
disease onset, relatively late in the disease process. Moreover, consider-
ing that ALS is a multifactorial disorder, targeting a limited number of
affected pathways with a single therapeutic may not be as efﬁcacious
as combination therapy. Although many agents have shown signiﬁcant
diseasemodifying effects inmice, to date nonehas successfully translat-
ed into the clinic in positive human trials [207,208].
There are likely to be several reasons for this lack of translation of
therapeutics from ALS models to patients. For example, there are
signiﬁcant differences in the design of animal trials and those
Table 3
Summary of therapeutics recently trialled in rodent models of ALS. Where percentage improvements are quoted, values were rounded down to the nearest whole number on the
side of caution. Where dose-dependent effects were evident, the greatest improvements are quoted. MN: motor neuron; nd: not described; pre: presymptomatically; post:
postsymptomatically.
Drug, treatment Model Delays onset? Extends survival? Improves MN
survival?
Reference
Excitotoxicity
Methionine sulfoximine, presymptomatically SOD1G93A mice nd Yes (8%) nd Ghoddoussi et al. [104]
Talampanel, pre- and postsymptomatically SOD1G93A mice nd nd Worsens Paizs et al. [105]
Dantrolene, presymptomatically SOD1G93A mice nd No No Staats et al. [106]
Glycyrrhetinic acid, presymptomatically SOD1G93A mice nd Yes Yes Takuechi et al. [107]
D-serine, pre- and postsymptomatically SOD1G93A mice Yes
(presymptomatic
treatment)
Yes nd Thompson et al. [108]
Mitochondrial function
Uridine, presymptomatically SOD1G93A mice Yes Yes (15/17%, dose-dependent) Yes Amante et al. [109]
Dichloroacetate, presymptomatically SOD1G93A mice nd Yes (9% males, 6% females) Yes Miquel et al. [110]
Oxidative stress
M30, presymptomatically SOD1G93A mice Yes (4%) Yes (6%) nd Kuperschmidt et al. [111]
Rosmarinic acid, presymptomatically SOD1G93A mice No Yes nd Shimojo et al. [112]
Metallothionein-III, onset SOD1G93A mice nd Yes (10%) Yes Hasimoto et al. [113]
Metformin, presymptomatically SOD1G93A mice No No nd Kaneb et al. [114]
VK-28, presymptomatically SOD1G93A mice Yes (11%) Yes (10%) nd Wang et al. [115]
M30, presymptomatically SOD1G93A mice Yes (5%) Yes (6%) Yes Wang et al. [115]
Diapocynin, pre- and postsymptomatically SOD1G93A mice nd Pre: No
Post: 8%
nd Trumbull et al. [116]
Apocynin, pre- and postsymptomatically SOD1G93A mice nd Yes nd Trumbull et al. [116]
CuII (atsm), pre- and postsymptomatically SOD1G93A mice, low
copy
Yes Pre:13%
Post:11%
Yes (pre) Soon et al. [117]
Trophic support
IGF-1:TTC, presymptomatically SOD1G93A mice No No nd Chian et al. [118]
IGF-1 (AAV2-mediated), onset SOD1G93A rats No No Yes Franz et al. [119]
MGF, presymptomatically SOD1G93A mice nd nd Yes Riddoch-Contreras et al.
[120]
Lead, presymptomatically SOD1G93A mice No Yes (10%) nd Barbeito et al. [121]
VEGF (AAV4-mediated), onset SOD1G93A mice nd Yes
Males 7%
Females 16%
nd Dodge et al. [122]
IGF-1 (AAV4-mediated), onset SOD1G93A mice nd Yes (10%) nd Dodge et al. [122]
VEGF+IGF-1 (AAV4-mediated), onset SOD1G93A mice nd Yes (8%) nd Dodge et al. [122]
BDNF:TTC, presymptomatic SOD1G93A mice Yes (28%) Yes (14%) Yes Calvo et al. [123]
Exendin-4, presymptomatically SOD1G93A mice No No Yes Li et al. [124]
PEG-modiﬁed IGF-1, presymptomatic SOD1G93A mice, low
copy
Yes (9%) Yes (4%) nd Saenger et al. [125]
Protein misfolding/aggregation/degradation
Immunisation against misfolded SOD1
(D3H5), presymptomatically or onset
SOD1G93A mice Yes Yes (when treated
presymptomatically)
nd Gros-Louis et al. [126]
Immunisation against misfolded SOD1
(A5C3), presymptomatically or onset
SOD1G93A mice nd No nd Gros-Louis et al. [126]
Rapamycin, presymptomatically SOD1G93A mice Hastens Decreases Worsens Zhang et al. [127]
Aryloxanyl pyrazolone derivative,
presymptomatically
SOD1G93A mice nd Yes (16%, dose-dependent) nd Chen et al. [128]
Resveratrol, presymptomatically SOD1G93A mice Yes (9%) Yes (7%) Yes Han et al. [129]
Recombinant Hsp70, presymptomatic SOD1G93A mice nd nd nd Gifondorwa et al. [130]
Cyclohexane-1,2-diones, presymptomatically SOD1G93A mice nd Yes (13%, dose-dependent) nd Zhang et al. [131]
Immunisation against misfolded SOD1
(SEDI), presymtomatically
SOD1G93A mice No No nd Liu et al. [132]
Arimoclomol, presymptomatically SOD1G93A mice nd nd Yes Lu et al. [133]
Immunisation against wildtype apo-SOD1 SOD1G93A mice, low
copy
Yes (16%) Yes (6%) nd Takeuchi et al. [134]
Immunisation against mutant apo-SOD1 SOD1G93A mice, low
copy
Yes (9%) Yes (4%) Yes Takeuchi et al. [134]
Immunisation against misfolded SOD1
(SEDI), presymptomatically
SOD1G37R mice Yes (8%) Yes (11%) Yes Liu et al. [132]
Rapamycin, presymptomatically TDP-43WT mice nd nd nd Wang et al. [79]
Non-cell autonomous/inﬂammation
Revlimid, onset SOD1G93A mice nd Yes (12%) Yes Neymotin et al. [135]
GCSF (AAV1/2-medaited),
presymptomatically
SOD1G93A mice Yes Yes (10%) Yes Henriques et al. [136]
Monoclonal antibody against CD40L,
presymptomatically
SOD1G93A mice Yes (7%) Yes (7%) nd Lincecum et al. [137]
Minocycline, pre- and postsymptomatically
and onset
GFAP-luc/SOD1G93A
mice
nd Yes (presymptomatic: 6%) No Keller et al. [138]
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Table 3 (continued)
Drug, treatment Model Delays onset? Extends survival? Improves MN
survival?
Reference
Pegﬁlgrastim, presymptomatically SOD1G93A mice No No nd Naumenko et al. [139]
Pegﬁlgrastim, presymptomatically SOD1G93A mice No Yes (6%) nd Pollari et al. [140]
Melittin, pre- and postsymptomatically SOD1G93A mice Yes No nd Yang et al. [141]
Anti-Ly6C monoclonal antibody, onset SOD1G93A mice nd Yes (16%) nd Butovsky et al. [142]
Non-cell autonomous/inﬂammation
Caffeic acid phenethyl ester, postsymptomatically SOD1G93A mice nd Yes (7%) nd Fontanilla et al. [143]
MCSF, presymptomatically SOD1G37R mice nd Decreases No Gowing et al. [144]
Rosiglitazone, onset FUSR521C rats nd nd nd Huang et al. [74]
Other
Valproic acid, presymptomatically SOD1G93A mice No No nd Crochemore et al. [145]
Retinoic acid, presymptomatically SOD1G93A mice nd Decreases nd Crochemore et al. [145]
L-arginine, early presymptomatic and
presymptomatic
SOD1G93A mice Yes Early pre (20%)
Pre (9%)
Yes (Pre) Lee et al. [146]
ActRIIB.mFc, presymptomatic and onset SOD1G93A mice Yes (pre, 10%) No nd Morrison et al. [147]
Activated protein C, onset SOD1G93A mice nd Yes (dose-dependent, 22%) nd Zhong et al. [148]
SUN N8075, presymptomatically SOD1G93A mice Yes Yes (11%) Yes Shimazawa et al. [149]
S-adenosyl methionine, presymptomatically SOD1G93A mice nd No nd Suchy et al. [150]
TTC, presymptomatically SOD1G93A mice Yes (20%) Yes (12%) Yes Calvo et al. [123]
Diallyl trisulﬁde, onset SOD1G93A mice nd Yes (5%) nd Guo et al. [151]
CDDO ethylamide, early presymptomatically,
or onset
SOD1G93A mice nd Yes
Early pre (16%)
Onset (13%)
nd Neymotin et al. [152]
CDDO triﬂuoroethylamide, early
presymptomatically, or onset
SOD1G93A mice nd Yes
Early pre (14%)
Onset (13%)
nd Neymotin et al. [152]
SK-PC-B70M, presymptomatically SOD1G93A mice nd Yes, in early stages Yes Seo et al. [153]
Trichostatin A, onset SOD1G93A mice nd Yes (7%) Yes Yoo & Ko [154]
Nandrolone SOD1G93A mice nd nd nd Cappello et al. [155]
AGS-499, presymptomatically SOD1G93A mice Yes Yes (dose-dependent, 16%) Yes Eitan et al. [156]
DHEA, presymptomatically SOD1G93A rats No No nd Hayes-Punzo et al. [157]
Davunetide, neonatal and presymptomatic SOD1G93A mice nd Yes (neonatal: 6%) nd Jouroukhin et al. [158]
Dasatinib, presymptomatically SOD1G93A mice nd Yes (at high dose) Yes Katsumata et al. [159]
Methimazole, early presymptomatic SOD1G93A mice No No nd Li et al. [160]
PRE-084, presymptomatically SOD1G93A mice nd Yes (dose-dependent, 16%) Yes Mancuso et al. [161]
Olexisome, presymptomatically SOD1G93A mice nd nd Yes Sunyach et al. [162]
P7C3A20, early presymptomatically SOD1G93A mice nd No Yes Tesla et al. [163]
Dihydrotestosterone, presymptomatic SOD1G93A mice nd Yes (5%) Yes Yoo & Ko [164]
Bromocriptine methylate, onset SOD1H46R mice nd Yes (2%) Yes Tanaka et al. [165]
CPN-9, onset SOD1H46R mice nd Yes (dose-dependent, 16%) Yes Kanno et al. [166]
SUN N8075, presymptomatically SOD1H46R rats Yes Yes (6%) nd Shimazawa et al. [149]
Multiple pathways
Lithium chloride, presymptomatically SOD1G93A mice No No nd Gill et al. [167]
Lithium chloride, presymptomatically SOD1G93A mice nd nd nd Ferrucci et al. [168]
Vitamin D3 deﬁciency, early presymptomatically SOD1G93A mice Yes (6%) nd nd Solomon et al. [169]
Methylene blue, onset SOD1G93A mice No No No Audet et al. [170]
Methylene blue and lithium, onset SOD1G93A mice No No No Audet et al. [170]
Methylene blue, presymptomatically SOD1G93A mice Yes (8%) Yes (5%) Yes Dibaj et al. [171]
DL-NBP, onset SOD1G93A mice nd Yes (dose-dependent, 42%) Yes Feng et al. [172]
Excess vitamin D3, early presymptomatic SOD1G93A mice No No nd Gianforcaro & Hamadeh
[173]
Methylene blue, presymptomatically SOD1G93A mice Yes (5% in
females)
No nd Lougheed & Turnbull
[174]
Methylene blue, onset TDP-43G348C mice nd nd nd Audet et al. [170]
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whichmay account for some of the discrepancies. In addition, the ma-
jority of pre-clinical trials undertaken to date have relied on the use of
the SOD1G93A mouse model of ALS [24], which has signiﬁcant over-
expression of the mutant protein to produce a phenotype that recapit-
ulates many features of ALS, and has a rapid disease course. However,
another line of these mice with a reduced copy number (SOD1G93Adl)
is available, in which the onset of disease-like symptoms is delayed
and shows slower progression [209]. It is possible that this transgenic
model may more accurately recapitulate at least mutant SOD1–FALS.
However, it is also important to consider two important issues: ﬁrstly,
mutations in SOD1 only account for a small proportion of total ALS
cases (approximately 2%), and therapeutics which show promising
results in SOD1 models may not be appropriate for the majority of
FALS or SALS cases. Secondly, and interlinked, as we are in the infancy
of understanding the function and dysfunction of other ALS-associatedproteins, such as TDP-43, FUS and VCP, it may be the case that the
pathomechanisms are known to be relevant in SOD1–ALS may not be
signiﬁcant for most ALS patients.
However, with the recent expansion in our understanding of the
genetic causes of FALS, it is hoped that new models which mimic
ALS will soon become available. This will permit therapeutic studies
to be undertaken in multiple models of ALS, which should result in
greater assurance of their efﬁcacy on ALS-relevant mechanisms prior
to testing in human trials. Furthermore, genomic humanisation of
mice offers an alternative strategy for modelling human disease in
rodents [210], as does N-ethyl-N-nitrosourea mutagenesis, which
causes pointmutations in endogenous genes, resulting in the expression
of mutant proteins at physiologically relevant levels [211–213].
As therapeutic interventions to date have had limited translational
success (comprehensively reviewed [207]), it is clear that additional
rodent models of ALS, which accurately model the human disease,
1432 P. McGoldrick et al. / Biochimica et Biophysica Acta 1832 (2013) 1421–1436are required. This may require novel approaches in the development
of models to overcome some of the problems that we now know are
associated with overexpression models. Studies involving TDP-43, FUS
and VCP in themodelling of ALS in rodents are not straightforward, and
development of new, reliable rodent models of ALS may take time,
despite the urgent requirement for these additional models of ALS.References
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